Literature DB >> 23939379

Histone deacetylase regulation of ATM-mediated DNA damage signaling.

K Ted Thurn1, Scott Thomas, Paromita Raha, Ian Qureshi, Pamela N Munster.   

Abstract

Ataxia-telangiectasia mutated (ATM) is a major regulator of the DNA damage response. ATM promotes the activation of BRCA1, CHK2, and p53 leading to the induction of response genes such as CDKN1A (p21), GADD45A, and RRM2B that promote cell-cycle arrest and DNA repair. The upregulation of these response genes may contribute to resistance of cancer cells to genotoxic therapies. Here, we show that histone deacetylases (HDAC) play a major role in mitigating the response of the ATM pathway to DNA damage. HDAC inhibition decreased ATM activation and expression, and attenuated the activation of p53 in vitro and in vivo. Select depletion of HDAC1 and HDAC2 was sufficient to modulate ATM activation, reduce GADD45A and RRM2B induction, and increase sensitivity to DNA strand breaks. The regulation of ATM by HDAC enzymes therefore suggests a vital role for HDAC1 and HDAC2 in the DNA damage response, and the potential use of the ATM pathway as a pharmacodynamic marker for combination therapies involving HDAC inhibitors. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939379      PMCID: PMC3821775          DOI: 10.1158/1535-7163.MCT-12-1242

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  ATM is a target for positive regulation by E2F-1.

Authors:  Eli Berkovich; Doron Ginsberg
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

2.  Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair.

Authors:  Sheetal Singh; Hongan Le; Shyh-Jen Shih; Bay Ho; Andrew T Vaughan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

3.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.

Authors:  Anupama Munshi; John F Kurland; Takashi Nishikawa; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Sheikh Ismail; Craig Stevens; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

5.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.

Authors:  Jun Sato; Takashi Kimura; Takuro Saito; Takayuki Anazawa; Akira Kenjo; Yoshihiro Sato; Takao Tsuchiya; Mitsukazu Gotoh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-09       Impact factor: 7.027

6.  Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts.

Authors:  Peng Ji; Victor Yeh; Tzutzuy Ramirez; Maki Murata-Hori; Harvey F Lodish
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

7.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Hiroko Saito; Yasushi Yatabe; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

8.  Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex.

Authors:  Ji-Hoon Lee; Tanya T Paull
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

9.  Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

Authors:  Chang-Shi Chen; Yu-Chieh Wang; Hsiao-Ching Yang; Po-Hsien Huang; Samuel K Kulp; Chih-Cheng Yang; Yen-Shen Lu; Shigemi Matsuyama; Ching-Yu Chen; Ching-Shih Chen
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  47 in total

1.  A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.

Authors:  S Thomas; R Aggarwal; T Jahan; C Ryan; T Troung; A M Cripps; P Raha; K T Thurn; S Chen; J A Grabowsky; J Park; J Hwang; A Daud; P N Munster
Journal:  Ann Oncol       Date:  2016-02-21       Impact factor: 32.976

2.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

3.  Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy.

Authors:  Benny Johnson; Ari Vanderwalde; Nader Javadi; Rebecca Feldman; Sandeep Bobby Reddy
Journal:  J Gastrointest Oncol       Date:  2016-04

Review 4.  DNA damage in the oligodendrocyte lineage and its role in brain aging.

Authors:  Kai-Hei Tse; Karl Herrup
Journal:  Mech Ageing Dev       Date:  2016-05-26       Impact factor: 5.432

Review 5.  DNA damage response is hijacked by human papillomaviruses to complete their life cycle.

Authors:  Shi-Yuan Hong
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

6.  Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.

Authors:  Bryan C Mounce; Wadzanai P Mboko; Adam J Kanack; Vera L Tarakanova
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

Review 7.  MTA family of proteins in DNA damage response: mechanistic insights and potential applications.

Authors:  Da-Qiang Li; Yinlong Yang; Rakesh Kumar
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

Review 8.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

9.  Damaged DNA-binding protein down-regulates epigenetic mark H3K56Ac through histone deacetylase 1 and 2.

Authors:  Qianzheng Zhu; Aruna Battu; Alo Ray; Gulzar Wani; Jiang Qian; Jinshan He; Qi-en Wang; Altaf A Wani
Journal:  Mutat Res       Date:  2015-01-24       Impact factor: 2.433

Review 10.  Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.

Authors:  Kristy R Stengel; Scott W Hiebert
Journal:  Antioxid Redox Signal       Date:  2014-06-26       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.